Bipolar I depression
bipolar II depression
approved for both
CAPLYTA is an FDA-approved treatment option for bipolar I and bipolar II depression in adults as monotherapy and adjunctive therapy with lithium or valproate.1
Consistent Safety Profile Across Trials
Attend a CAPLYTA speaker program
Watch a peer-led presentation on the CAPLYTA clinical profile